Integrin α9 gene promoter is hypermethylated and downregulated in nasopharyngeal carcinoma

Imran Nawaz1,2, Li-Fu Hu1, Zi-Ming Du1,3

  • 1Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.

Oncotarget
|September 16, 2015
PubMed

Insights

Integrin alpha 9 (ITGA9) is a tumor suppressor gene silenced by promoter methylation in nasopharyngeal carcinoma (NPC). ITGA9 methylation may serve as a potential biomarker for early NPC detection.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Epigenetic silencing of tumor suppressor genes (TSGs) via promoter methylation is an early event in carcinogenesis.
  • Human chromosome 3 harbors TSGs implicated in various cancers, including nasopharyngeal carcinoma (NPC).

Purpose of the Study:

  • To identify and validate candidate TSGs on chromosome 3 in NPC.
  • To investigate the role of ITGA9 and WNT7A in NPC development and their potential as diagnostic markers.

Main Methods:

  • NotI microarray analysis to identify candidate TSGs.
  • 5'-aza-2' deoxycytidine treatment to assess gene expression restoration.
  • Immunostaining for protein expression analysis.
  • Methylation-specific PCR (MSP) to detect promoter methylation.

Main Results:

  • ITGA9 and WNT7A were validated as candidate TSGs; their expression was restored by demethylation treatment.
  • ITGA9 showed significant promoter hypermethylation and a 4.9-fold downregulation in NPC tumors compared to adjacent normal tissue.
  • ITGA9 methylation was detected in 56% of EBV-positive NPC cases with 100% specificity.

Conclusions:

  • ITGA9 functions as a tumor suppressor gene in NPC, with its silencing mediated by promoter methylation.
  • ITGA9 methylation represents a promising biomarker for the early detection of nasopharyngeal carcinoma.